Previous Next

2024-02-14

Ensitrelvir in mild to moderate Covid-19

Infectiology

In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, investigators evaluated the efficacy and safety of ensitrelvir in 1,821 patients with mild-to-moderate Covid-19. Patients were randomized to receive ensitrelvir 125 mg once daily (375 mg on day 1), ensitrelvir 250 mg once daily (750 mg on day 1) or placebo for 5 days. The primary endpoint was the duration of resolution of the five main symptoms of infection. Ensitrelvir 125 mg, initiated within 72 hours of the onset of the first signs of illness, reduced the duration of symptoms by around 1 day, compared with placebo.

Source(s) :
Hiroshi Yotsuyanagi et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. JAMA Netw Open. 2024 Feb 5;7(2):e2354991. ;

Last press reviews


Eat without fear: anti-ige antibody omalizumab, a new weapon against food allergies

#Omalizumab #FoodAllergies #IgE #Anaphylaxis #Immunotherapy  ...

Vitamin D and tuberculosis: an overestimated protection?

By Ana Espino | Published on July 18, 2025 | 2 min read

Outdoor temperature and severe hyponatremia: a growing threat in the age of climate change

By Lila Rouland | Published on July 17, 2025 | 3 min read  ...